JP2022512541A5 - - Google Patents
Info
- Publication number
- JP2022512541A5 JP2022512541A5 JP2021511588A JP2021511588A JP2022512541A5 JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5 JP 2021511588 A JP2021511588 A JP 2021511588A JP 2021511588 A JP2021511588 A JP 2021511588A JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cancer
- binding
- pharmaceutical composition
- extracellular domain
- Prior art date
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724600P | 2018-08-29 | 2018-08-29 | |
| US62/724,600 | 2018-08-29 | ||
| US201862734951P | 2018-09-21 | 2018-09-21 | |
| US62/734,951 | 2018-09-21 | ||
| US201962793235P | 2019-01-16 | 2019-01-16 | |
| US62/793,235 | 2019-01-16 | ||
| US201962832830P | 2019-04-11 | 2019-04-11 | |
| US62/832,830 | 2019-04-11 | ||
| US201962890217P | 2019-08-22 | 2019-08-22 | |
| US62/890,217 | 2019-08-22 | ||
| PCT/US2019/048923 WO2020047328A1 (en) | 2018-08-29 | 2019-08-29 | Combination therapies comprising pd-1-based chimeric proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512541A JP2022512541A (ja) | 2022-02-07 |
| JP2022512541A5 true JP2022512541A5 (https=) | 2022-09-06 |
| JPWO2020047328A5 JPWO2020047328A5 (https=) | 2022-09-06 |
Family
ID=69644684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511588A Pending JP2022512541A (ja) | 2018-08-29 | 2019-08-29 | Ｐｄ－１系キメラタンパク質を含む併用療法 |
| JP2021511586A Ceased JP2022511286A (ja) | 2018-08-29 | 2019-08-29 | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511586A Ceased JP2022511286A (ja) | 2018-08-29 | 2019-08-29 | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210379153A1 (https=) |
| EP (2) | EP3844176A4 (https=) |
| JP (2) | JP2022512541A (https=) |
| CN (2) | CN112839952A (https=) |
| AU (2) | AU2019327494A1 (https=) |
| CA (2) | CA3109354A1 (https=) |
| IL (2) | IL281095A (https=) |
| MX (2) | MX2021002294A (https=) |
| WO (2) | WO2020047319A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020047319A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
| WO2021195472A1 (en) * | 2020-03-26 | 2021-09-30 | Aetio Biotherapy, Inc. | Bi-specific fusion proteins for depletion of regulatory t cells |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| MX2023003142A (es) * | 2020-09-17 | 2023-05-17 | Shattuck Labs Inc | Dosificacion clinica de proteina quimerica sirp1a. |
| AU2021378152A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
| EP4274852A4 (en) * | 2021-01-11 | 2025-02-26 | Eutilex Co., Ltd. | BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF |
| EP4301470A4 (en) * | 2021-03-05 | 2025-01-22 | Shattuck Labs, Inc. | COMBINATION THERAPIES WITH SIRP-ALPHA-BASED CHIMERIC PROTEINS |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JPH07509694A (ja) | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| NZ592420A (en) * | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| ES2914814T3 (es) * | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| EA038981B1 (ru) * | 2013-03-14 | 2021-11-17 | Икан Скул Оф Медсин Эт Маунт Синай | Вирусы болезни ньюкасла и их применение |
| KR20160093012A (ko) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
| RU2766200C1 (ru) * | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| CA3047394A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| LT3565579T (lt) * | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
| MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| WO2020047319A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
-
2019
- 2019-08-29 WO PCT/US2019/048913 patent/WO2020047319A1/en not_active Ceased
- 2019-08-29 US US17/266,015 patent/US20210379153A1/en not_active Abandoned
- 2019-08-29 EP EP19855662.3A patent/EP3844176A4/en not_active Withdrawn
- 2019-08-29 JP JP2021511588A patent/JP2022512541A/ja active Pending
- 2019-08-29 AU AU2019327494A patent/AU2019327494A1/en not_active Abandoned
- 2019-08-29 US US17/266,356 patent/US20210309744A1/en not_active Abandoned
- 2019-08-29 JP JP2021511586A patent/JP2022511286A/ja not_active Ceased
- 2019-08-29 MX MX2021002294A patent/MX2021002294A/es unknown
- 2019-08-29 CA CA3109354A patent/CA3109354A1/en active Pending
- 2019-08-29 CA CA3109346A patent/CA3109346A1/en active Pending
- 2019-08-29 CN CN201980067213.7A patent/CN112839952A/zh active Pending
- 2019-08-29 AU AU2019327493A patent/AU2019327493A1/en not_active Abandoned
- 2019-08-29 MX MX2021002292A patent/MX2021002292A/es unknown
- 2019-08-29 EP EP19853526.2A patent/EP3844175A4/en not_active Withdrawn
- 2019-08-29 CN CN201980063224.8A patent/CN112771067A/zh active Pending
- 2019-08-29 WO PCT/US2019/048923 patent/WO2020047328A1/en not_active Ceased
-
2021
- 2021-02-24 IL IL281095A patent/IL281095A/en unknown
- 2021-02-25 IL IL281132A patent/IL281132A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512541A5 (https=) | ||
| JP2022511286A5 (https=) | ||
| CN110869388B (zh) | 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 | |
| AU2017247880B2 (en) | Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion | |
| JP2024532485A (ja) | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| JP7464525B2 (ja) | 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質 | |
| JP7102670B2 (ja) | 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合 | |
| JP2020530298A5 (https=) | ||
| US20160235842A1 (en) | Medical uses of cd38 agonists | |
| WO2021023108A1 (zh) | 一种抗pd-1抗体及其医药用途 | |
| JP2017506217A (ja) | 標的ＴＧＦβ阻害 | |
| US20240018248A1 (en) | An ltbr agonist in combination therapy against cancer | |
| JP7362614B2 (ja) | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 | |
| CN115192718A (zh) | 抗cd47的单克隆抗体及其用途 | |
| AU2017239038B2 (en) | Administration of an anti-LGR5 monoclonal antibody | |
| JP2022512539A5 (https=) | ||
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| JPWO2020047328A5 (https=) | ||
| CN114616251A (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| JP7832689B2 (ja) | Ｐｄ－１ポリペプチド変異体 | |
| JPWO2020047319A5 (https=) | ||
| JP2022503621A5 (https=) | ||
| EP4545631A1 (en) | Immune cell expressing immune checkpoint regulator, and use thereof | |
| TWI887285B (zh) | 抗ｇａｒｐ抗體與免疫調節劑之組合及其用途 |